These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 30166504)

  • 1. [Impact of antiangiogenic therapy on ocular blood flow and microcirculation in diabetic macular edema].
    Neroev VV; Kiseleva TN; Okhotsimskaya TD; Fadeeva VA; Ramasanova KA
    Vestn Oftalmol; 2018; 134(4):3-10. PubMed ID: 30166504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of intravitreal injection of ranibizumab on choroidal structure and blood flow in eyes with diabetic macular edema.
    Okamoto M; Yamashita M; Ogata N
    Graefes Arch Clin Exp Ophthalmol; 2018 May; 256(5):885-892. PubMed ID: 29492689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of Intravitreal Ranibizumab for Diabetic Macular Edema with Serous Retinal Detachment.
    Kaya M; Karahan E; Ozturk T; Kocak N; Kaynak S
    Korean J Ophthalmol; 2018 Aug; 32(4):296-302. PubMed ID: 30091308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multifocal electroretinography changes at the 1-year follow-up in a cohort of diabetic macular edema patients treated with ranibizumab.
    Baget-Bernaldiz M; Romero-Aroca P; Bautista-Perez A; Mercado J
    Doc Ophthalmol; 2017 Oct; 135(2):85-96. PubMed ID: 28779336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The macular function and structure in patients with diabetic macular edema before and after ranibizumab treatment.
    Nowacka B; Kirkiewicz M; Mozolewska-Piotrowska K; Lubiński W
    Doc Ophthalmol; 2016 Apr; 132(2):111-22. PubMed ID: 27000269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imaging retinal inflammatory biomarkers after intravitreal steroid and anti-VEGF treatment in diabetic macular oedema.
    Vujosevic S; Torresin T; Bini S; Convento E; Pilotto E; Parrozzani R; Midena E
    Acta Ophthalmol; 2017 Aug; 95(5):464-471. PubMed ID: 27775223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional and morphological changes in diabetic macular edema over the course of anti-vascular endothelial growth factor treatment.
    Reznicek L; Cserhati S; Seidensticker F; Liegl R; Kampik A; Ulbig M; Neubauer AS; Kernt M
    Acta Ophthalmol; 2013 Nov; 91(7):e529-36. PubMed ID: 23647578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment.
    Bressler SB; Ayala AR; Bressler NM; Melia M; Qin H; Ferris FL; Flaxel CJ; Friedman SM; Glassman AR; Jampol LM; Rauser ME;
    JAMA Ophthalmol; 2016 Mar; 134(3):278-85. PubMed ID: 26746868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of macular vascular density and foveal avascular zone changes by optical coherence tomography angiography (OCT-A) after intravitreal dexamethasone implant in diabetic macular edema resistant to Anti-VEGF treatment.
    Ceylan A; Dogan ME; Demircan A; Akar Y
    Int Ophthalmol; 2022 Nov; 42(11):3579-3588. PubMed ID: 35737210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optical Coherence Tomography Angiography Analysis of the Foveal Avascular Zone and Macular Vessel Density After Anti-VEGF Therapy in Eyes With Diabetic Macular Edema and Retinal Vein Occlusion.
    Ghasemi Falavarjani K; Iafe NA; Hubschman JP; Tsui I; Sadda SR; Sarraf D
    Invest Ophthalmol Vis Sci; 2017 Jan; 58(1):30-34. PubMed ID: 28114569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The effect of intravitreally administered angiogenesis inhibitor on the concentration of angiotensin-converting enzyme in the blood serum and lacrimal fluid in patients with diabetic macular edema].
    Neroev VV; Chesnokova NB; Okhotsimskaya TD; Ryabina MV; Fadeeva VA; Pavlenko TА; Beznos OV
    Probl Endokrinol (Mosk); 2019 Jun; 65(2):72-78. PubMed ID: 31271708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of inner and outer retinal thickness in patients receiving intravitreal ranibizumab injections for diabetic macular edema.
    Dursun A; Ozec AV; Kirboga K; Dursun FG; Toker MI; Erdogan H; Arici MK
    Eur J Ophthalmol; 2016; 26(1):48-53. PubMed ID: 26220809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment.
    Karst SG; Lammer J; Mitsch C; Schober M; Mehta J; Scholda C; Kundi M; Kriechbaum K; Schmidt-Erfurth U
    Graefes Arch Clin Exp Ophthalmol; 2018 Jan; 256(1):49-58. PubMed ID: 29080915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optical Coherence Tomography Angiography of DME and Its Association with Anti-VEGF Treatment Response.
    Lee J; Moon BG; Cho AR; Yoon YH
    Ophthalmology; 2016 Nov; 123(11):2368-2375. PubMed ID: 27613201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diabetic macular edema with neuroretinal detachment: OCT and OCT-angiography biomarkers of treatment response to anti-VEGF and steroids.
    Vujosevic S; Toma C; Villani E; Muraca A; Torti E; Florimbi G; Leporati F; Brambilla M; Nucci P; De Cilla' S
    Acta Diabetol; 2020 Mar; 57(3):287-296. PubMed ID: 31541333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Visual Outcomes Following Intravitreal Ranibizumab for Diabetic Macular Edema in a Pro Re Nata Protocol from Baseline: A Real-World Experience.
    James DGP; Mitkute D; Porter G; Vayalambrone D
    Asia Pac J Ophthalmol (Phila); 2019; 8(3):200-205. PubMed ID: 31165603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetic macular edema treated with ranibizumab following bevacizumab failure in Israel (DERBI study).
    Ehrlich R; Pokroy R; Segal O; Goldstein M; Pollack A; Hanhart J; Barak Y; Kehat R; Shulman S; Vidne O; Abu Ahmad W; Chowers I
    Eur J Ophthalmol; 2019 Mar; 29(2):229-233. PubMed ID: 29916263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Crossover Design for Comparative Efficacy: A 36-Week Randomized Trial of Bevacizumab and Ranibizumab for Diabetic Macular Edema.
    Wiley HE; Thompson DJ; Bailey C; Chew EY; Cukras CA; Jaffe GJ; Lee RW; Loken EK; Meyerle CB; Wong W; Ferris FL
    Ophthalmology; 2016 Apr; 123(4):841-9. PubMed ID: 26875003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced Benefit in Diabetic Macular Edema from AKB-9778 Tie2 Activation Combined with Vascular Endothelial Growth Factor Suppression.
    Campochiaro PA; Khanani A; Singer M; Patel S; Boyer D; Dugel P; Kherani S; Withers B; Gambino L; Peters K; Brigell M;
    Ophthalmology; 2016 Aug; 123(8):1722-1730. PubMed ID: 27236272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
    Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
    Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.